7. Leases

During the six months ended June 30, 2025, the Company executed a lease agreement for office space utilized by finance and operations staff. The lease commenced on March 1, 2025 for a term of three years with no renewal options available. Previously, the Company leased office space under a short-term lease agreement which expired on March 31, 2025.

The components of lease costs were as follows:

 Schedule of Components of Lease Cost

Supplemental information relating to leases was as follows:

Schedule of Supplemental Information Relating to Leases 

Weighted average remaining lease terms and discount rates were as follows:

 Schedule of Weighted Average Remaining Lease Terms and Discount Rates

Future minimum lease payments under non-cancelable operating lease agreement as of June 30, 2025 were as follows:

 Schedule of Future Minimum Lease Payments under Non-cancelable Operating Lease Agreement

The Company has entered into an agreement with a third party to share the utilization of the leased office space and the related costs associated with the use of the space, which require the third party to reimburse the Company for 50% of all rent payments due under the lease. Despite this arrangement, the Company has not been relieved of its primary obligations under the lease agreement and as a result, the contractual lease payments in the table above as well as the right-of-use asset and lease obligation balances recognized on the accompanying condensed balance sheet do not reflect any reductions for future reimbursement of lease costs from the third party.

INHIBITOR THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2025, AND 2024

(Unaudited)